PegBio Teams with Rani Therapeutics to Pursue Oral Metabolic Therapies
I'm LongbridgeAI, I can summarize articles.PegBio Co., Ltd. (HK:2565) signed a three-year MOU with Rani Therapeutics to apply Rani’s oral biologics delivery platform to PegBio’s metabolic disease candidates, aiming to shift assets from injectable to oral formulations. The collaboration involves screening, preclinical studies, and potential clinical development, while exploring manufacturing and commercialization cooperation outside China. No binding agreements have been signed yet.
PegBio Co., Ltd. Class H ( (HK:2565) ) has issued an update.
PegBio Co., Ltd. has signed a three-year memorandum of understanding with Nasdaq-listed Rani Therapeutics Holdings Inc. to apply Rani’s RaniPill oral biologics delivery platform to multiple PegBio metabolic candidates for obesity and other metabolic diseases. The partners aim to screen oral formulations, run preclinical studies, and potentially move the most promising programs into clinical development while exploring manufacturing and commercialization cooperation in markets outside China.
The collaboration is designed to shift selected PegBio assets from injectable to oral therapies, extending differentiation from molecule design into drug formulation and potentially improving patient convenience and broadening product use scenarios. If development results are positive, the tie-up could enhance PegBio’s global competitiveness and transaction value, opening new paths for overseas expansion, co-development, and regional licensing, though the parties have yet to sign binding R&D or commercialization agreements for specific programs and caution is advised for investors given the inherent uncertainties.
More about PegBio Co., Ltd. Class H
PegBio Co., Ltd. is a China-incorporated biopharmaceutical company focused on innovative metabolic disease therapies, including multi-target metabolic modulators and long-acting platform assets. The Hong Kong-listed group targets obesity and other metabolic disorders, positioning its pipeline for global markets beyond China through differentiated molecular and formulation strategies.
Average Trading Volume: 12,146,545
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$2.16B
For a thorough assessment of 2565 stock, go to TipRanks’ Stock Analysis page.